

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members














